HCPLive

Post-Fracture Targeting Boosts Osteoporosis Management

FRIDAY, April 26 (HealthDay News) -- A mail-based intervention targeting patients with recent frailty fractures and their physicians is a more cost-effective means of osteoporosis management than usual care, according to a simulation-based study published online April 17 in the Journal of Clinical Endocrinology & Metabolism.

Sumit R. Majumdar, MD, MPH, from the University of Alberta, in Edmonton, Canada, and colleagues developed hypothetical model simulations to assess the cost-effectiveness of interventions versus usual care for osteoporosis after a fragility fracture. Among the three scenarios were two inexpensive mail-based interventions, one directed at physicians and the other at physicians plus patients, with increased one-year osteoporosis treatment starting at 4 and 6 percent, respectively, versus usual care starts of 11 percent.

The researchers found that the physician intervention cost $7.12 per patient, while the cost was $8.45 for the physician plus patient intervention. For every 1,000 patients getting the physician intervention, there were two fewer fractures, two more quality-adjusted life-years (QALYs) gained, and $22,000 saved, compared with usual care. The simulation demonstrated that, for every 1,000 patients receiving the physician plus patient intervention, there was one fewer fracture and one more QALY gained, with $18,000 saved, compared to the physician intervention. Usual care was dominated by both interventions, which were cost-saving or highly cost-effective in 67 percent of 10,000 probabilistic simulations. The physician plus patient intervention was the most economical option even though it cost $1.33 more per patient than the physician intervention.

"Pragmatic mail-based interventions directed at patients with recent fractures and their physicians are a highly cost-effective means to improving osteoporosis management and both interventions dominated usual care," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$